Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations

BACKGROUND: Newly diagnosed patients with chronic myeloid leukaemia (CML) are currently treated with tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib or dasatinib. However, incomplete eradication of residual disease is a general problem of long-term TKI therapy. Activation of mouse haem...

Descripción completa

Detalles Bibliográficos
Autores principales: Glauche, I, Horn, K, Horn, M, Thielecke, L, Essers, M AG, Trumpp, A, Roeder, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364126/
https://www.ncbi.nlm.nih.gov/pubmed/22538973
http://dx.doi.org/10.1038/bjc.2012.142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364126/
https://www.ncbi.nlm.nih.gov/pubmed/22538973
http://dx.doi.org/10.1038/bjc.2012.142

Ejemplares similares